Biocon Ltd (BIOCON)
₹390.45
Mkt cap
₹64,764 Cr
P/E ratio
89.00
P/B
1.86
Div yield
0.13%
ROE
1.40%
ROCE
3.61%
EPS (TTM)
₹4.39
Book value
₹210
52W range
339–441
Sector
Healthcare
Price history
Previous close
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
NSE BIOCONBSE 532523
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−11.40% from high₹390
₹339+15.21% from low₹441
Current
₹390.45
Prev close
₹397.40
Day
−1.75%
Price performance
1D
−1.75%
1W
−5.23%
1M
−8.42%
3M
−6.22%
6M
+3.20%
1Y
+10.75%
YTD
−0.64%
Financials
Revenue, profit & margin
P/E ratio
89.0×
BIOCON is 162% above the sector median of 34.0×
BIOCON89.0×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,423 | 3,462 | 3,954 | 3,917 | 3,433 | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 | 4,173 | 4,517 | 4,336 | |
| Expenses | 2,741 | 2,745 | 3,051 | 3,004 | 2,812 | 2,905 | 3,070 | 3,339 | 3,176 | 3,460 | 3,340 | 3,496 | 3,489 | |
| Operating Profit | 681 | 717 | 903 | 913 | 620 | 685 | 752 | 1,078 | 766 | 835 | 834 | 1,020 | 847 | |
| OPM % | 20% | 21% | 23% | 23% | 18% | 19% | 20% | 24% | 19% | 19% | 20% | 23% | 20% | |
| Other Income | 94 | 134 | 587 | 40 | 1,166 | 58 | 53 | 57 | 62 | 81 | -176 | -28 | 41 | |
| Interest | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 | 210 | 232 | 213 | |
| Depreciation | 358 | 389 | 414 | 407 | 405 | 420 | 425 | 436 | 455 | 473 | 515 | 513 | 547 | |
| Profit before tax | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 | 171 | -68 | 248 | 128 | |
| Tax % | 19% | 19% | 7% | 30% | 25% | 72% | 48% | 6% | 8% | 22% | -24% | 20% | -7% | |
| Net Profit | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 | -52 | 199 | 137 | |
| EPS in Rs | 0.84 | 1.05 | 5.50 | 1.13 | 5.49 | -0.13 | 0.21 | 2.87 | 0.23 | 0.63 | 1.08 | 0.78 | 0.87 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.70% · closed higher next day 20 of last 59
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 10 Nov '23◦ | 9 Feb '24◦ | 16 May '24◦ | 9 Aug '24 | 30 Oct '24◦ | 31 Jan '25 | 8 May '25◦ | 7 Aug '25◦ | 11 Nov '25◦ | 12 Feb '26◦ | 7 May '26 | 5 Aug '26◦ |
| Earnings day | −0.02% | −2.45% | +0.03% | −0.65% | −1.43% | +1.55% | −1.40% | −5.72% | +5.40% | +0.77% | −0.48% | +2.68% |
| +1 day | +0.75% | −2.27% | −0.39% | −0.38% | −3.06% | +3.77% | −1.93% | −6.07% | +8.28% | +1.41% | +2.15% | +0.27% |
| +5 days | +2.77% | +6.46% | +4.48% | +1.67% | +0.19% | +11.19% | +1.43% | +0.03% | +6.49% | +2.37% | +12.52% | −1.22% |
| +15 days | +5.72% | +2.01% | +9.89% | +7.15% | +9.96% | −5.88% | +0.37% | −2.22% | +6.47% | +3.91% | +11.35% | −1.60% |
| +30 days | +8.77% | −6.14% | +16.97% | +9.20% | +9.43% | −6.65% | +5.01% | −1.29% | +3.44% | −2.63% | +10.16% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Re 0.50 Per Share | — | 3 Jul '26 | 3 Jul '26 |
Shareholding
as of Jun 202644.68%Promoter
Promoters44.68%0.23
FIIs8.14%0.62
DIIs23.33%0.68
Public23.75%0.35
Government0.05%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| BIOCON | ₹397.40 | 89.05 | 64,764 | 0.13% | 137 | +327.65% | 4,336 | +10.00% | 3.61% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts112
TranscriptAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026PPTFeb 2026PPTDec 2025PPTDec 2025TranscriptDec 2025PPTDec 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 31 Aug - Biocon to meet investors at Nomura Asian Credit Corporate Day 2026 on 04-Sep-26.Communication Regarding Remittance Of Final Dividend For The FY 2025-26 28 Aug - Biocon remitted final dividend of ₹0.50 per share for FY2025-26, approved at 48th AGM on August 6, 2026.Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 26 Aug - Mylan clarifies 9.2 crore Biocon shares sold on 14 July 2026; post-sale holding was nil.Company Statement 25 Aug - Biocon Biologics received Japan MHLW approval for pegfilgrastim biosimilar; Sandoz K.K. will exclusively market it.Company Statement 18 Aug - Biocon’s U.S. subsidiary won supplemental FDA approval for Yesintek prefilled autoinjectors on August 18, 2026.